Ad
related to: platinum resistant ovarian cancer guidelinesgotoper.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Mirvetuximab soravtansine is indicated for the treatment of adults with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. [2] [5] [6] Recipients are selected for therapy based on an FDA ...
If ovarian cancer recurs, it is considered partially platinum-sensitive or platinum-resistant, based on the time since the last recurrence treated with platins: partially platinum-sensitive cancers recurred 6–12 months after last treatment, and platinum-resistant cancers have an interval of less than 6 months.
It is indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with cisplatin and/or alkylating agent-based combination. [1] It is not considered a first-line treatment, [2] but it can be useful as salvage therapy. [3]
Immunotherapy's adoption in platinum-resistant ovarian cancer remains unsupported by studies, prompting a need for further investigation. [26] Nonetheless, evidence indicates that combining chemotherapy with the humanized anti- VEGF monoclonal antibody, bevacizumab, in the treatment of recurrent, persistent, or metastatic cervical cancer ...
Cisplatin is administered intravenously as short-term infusion in normal saline for treatment of solid and haematological malignancies. It is used to treat various types of cancers, including sarcomas, some carcinomas (e.g., small cell lung cancer, squamous cell carcinoma of the head and neck and ovarian cancer), lymphomas, bladder cancer, cervical cancer, [9] and germ cell tumors.
Vintafolide is an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. [1] It is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor, which is overexpressed on certain cancers, such as ovarian cancer, and a potent chemotherapy drug, vinblastine.
Pre-holiday deals might get all the buzz, but New Year's markdowns deserve some love, too! Especially the ones we're seeing over at the Amazon Winter Sale; with all-time low prices galore and big ...
Nanotechnology has been explored to deliver platinum more efficiently in the case of lipoplatin, which is introduced into the tumor sites thereby reducing the chance of toxicity. [8] Cisplatin was the first to be developed. [9] Cisplatin is particularly effective against testicular cancer; the cure rate was improved from 10% to 85%. [10]
Ad
related to: platinum resistant ovarian cancer guidelinesgotoper.com has been visited by 10K+ users in the past month